Instrumento Inactivo

Otros idiomas Aquinox Pharmaceuticals Inc Nasdaq

Acciones

Precio de cierre Nasdaq Otros sitios de cotización
-	-

03/06	La terapia génica de Neurogene para el síndrome de Rett elegida para el programa piloto de la FDA	MT
03/06	Neurogene Inc. anuncia que la terapia génica NGN-401 para el síndrome de Rett ha sido seleccionada por la FDA para iniciar un programa piloto	CI

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Neurogene to Participate in Upcoming Conferences	05/06
Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program	03/06
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program	03/06
Neurogene Inc. Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for Start Pilot Program	03/06
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates	13/05
Neurogene: Q1 Earnings Snapshot	10/05
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates	10/05
Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Neurogene : ASGCT NGN-401 Clinical Safety Poster	07/05
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting	07/05
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome During Asgct Annual Meeting	07/05
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting	22/04
North American Morning Briefing : Stocks Struggle After New Records	22/03
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates	18/03
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
North American Morning Briefing : Inflation -2-	15/03
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	04/03
Neurogene Inc. Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	04/03
Neurogene to Participate in Upcoming Investor Conferences	29/02
Neurogene Inc. Appoints Donna Cochener as Senior Vice President, General Counsel	21/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Aquinox Pharmaceuticals Inc Nasdaq

Acciones

Otros idiomas

Filtros